Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
-
GSK’s RSV vaccine Arexvy has received European Commission approval for use in adults aged 18 and over.
-
The decision expands eligibility beyond the previous focus on adults aged 60+ and those at higher risk.
-
The broader label significantly enlarges the potential patient pool for Arexvy across European markets.
LSE:GSK now has a materially wider opportunity for its RSV franchise in Europe, with Arexvy cleared for all adults from 18 upwards. The move comes as GSK shares trade around £21.8, with the stock reported as up 17.7% over the past week and 53.8% over the past year.
For investors watching vaccine exposure, this approval changes the scope of GSK’s adult respiratory offering in Europe. The broader indication could influence how RSV vaccines are adopted in routine adult immunisation programs and how GSK competes within the respiratory vaccine market over time.
Stay updated on the most important news stories for GSK by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on GSK.
LSE:GSK 1-Year Stock Price Chart
-
❌ Price vs Analyst Target: At £21.80, GSK trades about 15.5% above the £18.87 analyst consensus target.
-
✅ Simply Wall St Valuation: Simply Wall St estimates GSK is trading 50.4% below its fair value.
-
✅ Recent Momentum: The 30 day return is 14.8%, which signals positive short term momentum.
Check out Simply Wall St’s in depth valuation analysis for GSK.
-
📊 Broader adult approval for Arexvy in Europe widens GSK’s potential vaccine reach and may influence how investors view its respiratory portfolio.
-
📊 Investors may monitor uptake in adult immunisation programs, RSV market share trends and how earnings and the P/E of 15.3 compare with the pharmaceuticals industry average P/E of 24.0.
-
⚠️ Dividend sustainability and GSK’s higher debt level are flagged risks that could become more significant if RSV uptake or pricing does not match expectations.
For the full picture including more risks and rewards, check out the complete GSK analysis.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.